JOHNSON & JOHNSON
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
NJ
Business Address
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
Mailing Address
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
Phone
732-524-2455
Fiscal Year End
1228
EIN
221024240
Financial Overview
FY2025
$24.11B
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 13F-HR/A Institutional holdings amendment | March 18, 2026 | View on SEC |
| 13F-HR/A Institutional holdings amendment | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
Annual Reports
10-K
February 11, 2026
- Strong operational revenue growth of 6.5% to $85.2 billion, driven by Pharmaceuticals and MedTech.
- Successful Kenvue spin-off sharpened strategic focus on high-growth Pharmaceuticals and MedTech segments.
Insider Trading
STRONG SELL
7 insiders
17 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.